BRPI1006519A2 - formulação de anticorpos - Google Patents
formulação de anticorposInfo
- Publication number
- BRPI1006519A2 BRPI1006519A2 BRPI1006519A BRPI1006519A BRPI1006519A2 BR PI1006519 A2 BRPI1006519 A2 BR PI1006519A2 BR PI1006519 A BRPI1006519 A BR PI1006519A BR PI1006519 A BRPI1006519 A BR PI1006519A BR PI1006519 A2 BRPI1006519 A2 BR PI1006519A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody formulation
- antibody
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15833109P | 2009-03-06 | 2009-03-06 | |
| PCT/US2010/026410 WO2010102241A1 (en) | 2009-03-06 | 2010-03-05 | Antibody formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1006519A2 true BRPI1006519A2 (pt) | 2016-08-09 |
Family
ID=42154725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1006519A BRPI1006519A2 (pt) | 2009-03-06 | 2010-03-05 | formulação de anticorpos |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8318161B2 (pt) |
| EP (1) | EP2403874A1 (pt) |
| JP (1) | JP2012519706A (pt) |
| KR (1) | KR20110128333A (pt) |
| CN (1) | CN102414221A (pt) |
| AR (1) | AR076640A1 (pt) |
| AU (1) | AU2010221156A1 (pt) |
| BR (1) | BRPI1006519A2 (pt) |
| CA (1) | CA2754528A1 (pt) |
| CL (1) | CL2011002194A1 (pt) |
| IL (1) | IL214956A0 (pt) |
| MX (1) | MX2011009306A (pt) |
| PE (1) | PE20120359A1 (pt) |
| RU (1) | RU2011140498A (pt) |
| SG (1) | SG174258A1 (pt) |
| TW (1) | TW201039854A (pt) |
| WO (1) | WO2010102241A1 (pt) |
| ZA (1) | ZA201106503B (pt) |
Families Citing this family (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1043320A1 (zh) | 1999-06-01 | 2002-09-13 | Biogen, Inc. | Vla-1的一种阻塞性单系抗体，以及其治疗炎性失调的功用 |
| US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| UA83791C2 (ru) | 2001-04-13 | 2008-08-26 | Байоджен Айдек Ма Инк. | Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1 |
| AU2004229335C1 (en) | 2003-04-04 | 2010-06-17 | Genentech, Inc. | High concentration antibody and protein formulations |
| WO2006138181A2 (en) | 2005-06-14 | 2006-12-28 | Amgen Inc. | Self-buffering protein formulations |
| BRPI0712607A8 (pt) | 2006-05-25 | 2019-06-04 | Biogen Idec Inc | métodos de tratamento de acidente vascular cerebral |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| JP5828151B6 (ja) * | 2009-01-06 | 2018-09-19 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | アテローム性動脈硬化の処置のためのｂ細胞枯渇剤 |
| US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| AU2013202276B2 (en) * | 2009-12-21 | 2016-03-24 | Genentech, Inc. | Antibody formulation |
| BR112012013093A2 (pt) * | 2009-12-21 | 2017-12-12 | Genentech Inc | ''formulação farmacêutica aquosa estável, artigo, métodos para estabilizar um anticorpo, para tratamento de uma doença ou distúrbio em um indivíduo, para reduzir a agregação de um anticorpo monoclonal terapêutico e de fabricação de uma formulação farmaceutica, frasco e tanque de aço inoxidável |
| RS59830B1 (sr) | 2010-03-01 | 2020-02-28 | Bayer Healthcare Llc | Optimizovana monoklonska antitela protiv inhibitora puta faktora tkiva (tfpi) |
| CA2792125C (en) | 2010-03-22 | 2019-02-12 | Genentech, Inc. | Compositions and methods useful for stabilizing protein-containing formulations |
| CA2806252C (en) | 2010-07-29 | 2019-05-14 | Xencor, Inc. | Antibodies with modified isoelectric points |
| EA032336B1 (ru) | 2010-09-17 | 2019-05-31 | Баксалта Инкорпорейтид | Стабильная водная иммуноглобулиновая композиция и способ стабилизации иммуноглобулиновой композиции |
| CN106267189B (zh) * | 2010-10-06 | 2021-02-26 | 瑞泽恩制药公司 | 含有抗白介素-4受体(il-4r)的抗体的稳定制剂 |
| UA111731C2 (uk) * | 2010-10-06 | 2016-06-10 | Рідженерон Фармасьютікалз, Інк. | Стабілізована композиція, яка містить антитіло до рецептора інтерлейкіну-4 (іl-4r), варіанти |
| MX385311B (es) | 2011-01-28 | 2025-03-18 | Sanofi Biotechnology | Anticuerpos humanos frente a pcsk9 para su uso en métodos de tratamiento de grupos concretos de pacientes. |
| JP6211513B2 (ja) * | 2011-04-26 | 2017-10-11 | ジェネンテック， インコーポレイテッド | 自己免疫疾患の治療のための組成物及び方法 |
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| AR087305A1 (es) * | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| HUE069234T2 (hu) | 2011-09-16 | 2025-02-28 | Regeneron Pharma | Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| AR088579A1 (es) * | 2011-10-31 | 2014-06-18 | Genentech Inc | Formulaciones de anticuerpos |
| NZ627859A (en) | 2012-01-23 | 2015-09-25 | Regeneron Pharma | Stabilized formulations containing anti-ang2 antibodies |
| ES2732243T3 (es) * | 2012-02-16 | 2019-11-21 | Santarus Inc | Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A) |
| EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| AR092325A1 (es) | 2012-05-31 | 2015-04-15 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit |
| FR2994390B1 (fr) | 2012-08-10 | 2014-08-15 | Adocia | Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
| UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| US9474803B2 (en) | 2012-11-27 | 2016-10-25 | Alteogen Inc. | Composition for stabilizing fusion protein in which protein and FC domain are fused |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| CA2898100C (en) | 2013-01-14 | 2023-10-10 | Xencor, Inc. | Novel heterodimeric proteins |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| CA2897987A1 (en) * | 2013-01-15 | 2014-07-24 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
| US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
| EP2970486B1 (en) | 2013-03-15 | 2018-05-16 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| EP3019516B1 (en) | 2013-07-12 | 2018-11-14 | H. Hoffnabb-La Roche Ag | Elucidation of ion exchange chromatography input optimization |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| CN113350278B (zh) * | 2013-10-24 | 2023-03-24 | 阿斯利康(瑞典)有限公司 | 稳定的水性抗体配制品 |
| EP3068803B1 (en) | 2013-11-12 | 2021-01-20 | Sanofi Biotechnology | Dosing regimens for use with pcsk9 inhibitors |
| CA2938590C (en) | 2014-02-11 | 2023-10-17 | Visterra, Inc. | Antibody molecules to dengue virus and uses thereof |
| JP6775422B2 (ja) | 2014-03-28 | 2020-10-28 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３８及びｃｄ３に結合する二重特異性抗体 |
| US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
| US20160074515A1 (en) | 2014-06-20 | 2016-03-17 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| CN107206068A (zh) | 2014-07-16 | 2017-09-26 | 赛诺菲生物技术公司 | 用于治疗杂合型家族性高胆固醇血症(heFH)患者的方法 |
| SG11201702614SA (en) | 2014-10-01 | 2017-04-27 | Eagle Biolog Inc | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
| US9821059B2 (en) | 2014-10-17 | 2017-11-21 | Alteogen Inc. | Composition for stabilizing protein and pharmaceutical formulation comprising the same |
| WO2016077451A1 (en) | 2014-11-12 | 2016-05-19 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| SG11201704283PA (en) | 2014-11-26 | 2017-06-29 | Xencor Inc | Heterodimeric antibodies that bind cd3 and tumor antigens |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| JP2017536830A (ja) | 2014-11-26 | 2017-12-14 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３及びｃｄ３８に結合するヘテロ二量体抗体 |
| WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
| KR20240172758A (ko) | 2015-08-18 | 2024-12-10 | 리제너론 파아마슈티컬스, 인크. | 지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체 |
| JP7058219B2 (ja) | 2015-12-07 | 2022-04-21 | ゼンコア インコーポレイテッド | Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体 |
| JP7155009B2 (ja) | 2016-03-25 | 2022-10-18 | ビステラ， インコーポレイテッド | デングウイルスに対する抗体分子の製剤 |
| US10858422B2 (en) | 2016-05-31 | 2020-12-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
| WO2017210360A1 (en) | 2016-05-31 | 2017-12-07 | Cardiovax, Llc | Methods for diagnosing and treating systemic lupus erythematosus |
| MA45255A (fr) | 2016-06-14 | 2019-04-17 | Xencor Inc | Anticorps inhibiteurs de points de contrôle bispécifiques |
| KR20190020341A (ko) | 2016-06-28 | 2019-02-28 | 젠코어 인코포레이티드 | 소마토스타틴 수용체 2에 결합하는 이종이량체 항체 |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| BR112019007281A2 (pt) | 2016-10-14 | 2019-07-09 | Xencor Inc | proteína heterodimérica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica e para tratar câncer em um paciente |
| ES3064802T3 (en) | 2016-10-21 | 2026-04-29 | Amgen Inc | Pharmaceutical formulations and methods of making the same |
| RU2019138507A (ru) | 2017-05-02 | 2021-06-02 | Мерк Шарп И Доум Корп. | Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1 |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| AU2018291497A1 (en) | 2017-06-30 | 2020-01-16 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains |
| US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| AU2018366199A1 (en) | 2017-11-08 | 2020-05-28 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
| AU2018390418B2 (en) | 2017-12-19 | 2023-12-21 | Xencor, Inc. | Engineered IL-2 Fc fusion proteins |
| WO2019153200A1 (zh) | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| EP3774881A1 (en) * | 2018-04-02 | 2021-02-17 | Amgen Inc. | Erenumab compositions and uses thereof |
| AU2019247415A1 (en) | 2018-04-04 | 2020-10-22 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| BR112020020741A2 (pt) * | 2018-04-10 | 2021-01-19 | Dr. Reddy's Laboratories Limited | Formulação farmacêutica estável de um anticorpo, e, formulação de anticorpo alfa4beta7 estável. |
| CA3097593A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| JP2021520829A (ja) | 2018-04-18 | 2021-08-26 | ゼンコア インコーポレイテッド | ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＴＩＭ−３抗原結合ドメインを含む、ＴＩＭ−３標的化ヘテロ二量体融合タンパク質 |
| WO2019232081A1 (en) * | 2018-05-29 | 2019-12-05 | Abcentra, Llc | Compositions and methods for treatment of rheumatoid arthritis and accelerated atherosclerosis |
| CN112839672A (zh) * | 2018-07-02 | 2021-05-25 | 艾比中心有限责任公司 | 用于减少脂蛋白a形成以及治疗主动脉瓣硬化和主动脉狭窄的组合物和方法 |
| SG11202103192RA (en) | 2018-10-03 | 2021-04-29 | Xencor Inc | Il-12 heterodimeric fc-fusion proteins |
| CN113056482A (zh) | 2018-10-18 | 2021-06-29 | 默沙东公司 | 抗rsv抗体的制剂及其使用方法 |
| CN120842406A (zh) | 2018-10-31 | 2025-10-28 | 默沙东有限责任公司 | 抗人pd-1抗体晶体及其使用方法 |
| KR20210089215A (ko) | 2018-11-07 | 2021-07-15 | 머크 샤프 앤드 돔 코포레이션 | 항-lag3 항체 및 항-pd-1 항체의 공동-제제 |
| WO2020180726A1 (en) | 2019-03-01 | 2020-09-10 | Xencor, Inc. | Heterodimeric antibodies that bind enpp3 and cd3 |
| AU2020334880A1 (en) * | 2019-08-16 | 2022-03-24 | Regeneron Pharmaceuticals, Inc. | High concentration anti-C5 formulations |
| EP4058042A4 (en) * | 2019-11-12 | 2023-12-27 | Abcentra, LLC | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER |
| WO2021173537A1 (en) * | 2020-02-24 | 2021-09-02 | Medimmune, Llc | Formulations of anti-endothelial lipase antibodies |
| AU2021262609A1 (en) | 2020-05-01 | 2022-12-22 | Kashiv Biosciences, Llc | An improved process of purification of protein |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| CA3182940A1 (en) * | 2020-05-28 | 2021-12-02 | Kashiv Biosciences, Llc | An improved process of storing and preparing the protein formulation |
| IL300133A (en) | 2020-07-31 | 2023-03-01 | Genentech Inc | Anti-integrin antibody compositions in cell 7 and devices |
| KR20230156079A (ko) | 2021-03-09 | 2023-11-13 | 젠코어 인코포레이티드 | Cd3과 cldn6에 결합하는 이종이량체 항체 |
| US11859012B2 (en) | 2021-03-10 | 2024-01-02 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and GPC3 |
| KR102839278B1 (ko) * | 2022-03-02 | 2025-07-30 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Fviii 모방 이중특이적 항체의 월 1회 투여 방법 |
| KR102839225B1 (ko) * | 2022-03-02 | 2025-07-29 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Fviii 모방 이중특이적 항체의 주 1회 투여 방법 |
| KR102868672B1 (ko) * | 2022-03-02 | 2025-10-14 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Fviii 모방 이중특이적 항체를 2주마다 1회 투여하는 방법 |
| EP4609881A1 (en) * | 2022-10-26 | 2025-09-03 | Nihon Medi-Physics Co., Ltd. | Radioactive pharmaceutical composition |
| AU2024240129A1 (en) | 2023-03-17 | 2025-10-09 | Oxitope Pharma B.V. | Anti-phosphocholine antibodies and methods of use thereof |
| KR20250000093A (ko) * | 2023-06-23 | 2025-01-02 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Fviii 모방 이중특이적 항체의 격월 1회 투여 방법 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1064396A (en) * | 1975-02-18 | 1979-10-16 | Myer L. Coval | Fractional precipitation of gamma globulin with polyethylene glycol |
| US4075193A (en) * | 1976-11-26 | 1978-02-21 | Parke, Davis & Company | Process for producing intravenous immune globulin |
| AT359641B (de) | 1978-09-19 | 1980-11-25 | Immuno Ag | Verfahren zur herstellung eines intravenoes ver- abreichbaren antikoerperhaeltigen immunglobulin- praeparates |
| US4374763A (en) * | 1979-09-17 | 1983-02-22 | Morishita Pharmaceutical Co., Ltd. | Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof |
| US4499073A (en) * | 1981-08-24 | 1985-02-12 | Cutter Laboratories, Inc. | Intravenously injectable immune serum globulin |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
| US4597966A (en) | 1985-01-09 | 1986-07-01 | Ortho Diagnostic Systems, Inc. | Histidine stabilized immunoglobulin and method of preparation |
| US4940782A (en) * | 1987-06-08 | 1990-07-10 | G. D. Searle & Co. | Monoclonal antibodies against IgE-associated determinants, hybrid cell lines producing these antibodies, and use therefore |
| ATE82506T1 (de) | 1987-08-21 | 1992-12-15 | Imcera Group Inc | Stabilisierung von wachstumshormonen. |
| US4877608A (en) * | 1987-11-09 | 1989-10-31 | Rorer Pharmaceutical Corporation | Pharmaceutical plasma protein formulations in low ionic strength media |
| CA1331133C (en) * | 1988-03-01 | 1994-08-02 | Michael Jon Pikal | Pharmaceutical growth hormone formulations |
| EP0365685B1 (en) * | 1988-03-30 | 1995-01-18 | Toray Industries, Inc. | Freeze-dried composition comprising a horseradish peroxidase-labelled Fab' fragment of an anti-human interferon-beta monclonal antibody and trehalose; EIA kit containing the composition |
| US5215743A (en) * | 1988-04-13 | 1993-06-01 | Maninder Singh | Tumor necrosis factor formulations |
| US5096885A (en) * | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
| GB2218703B (en) * | 1988-05-10 | 1992-10-28 | Sumitomo Chemical Co | Human monoclonal antibody to p.aeruginosa: its production and use |
| WO1989011297A1 (en) | 1988-05-27 | 1989-11-30 | Centocor, Inc. | Freeze-dried formulation for antibody products |
| CA2049342A1 (en) | 1989-03-27 | 1990-09-28 | Sally Bolmer | Formulations for stabilizing of igm antibodies |
| ZA902663B (en) | 1989-04-07 | 1991-12-24 | Syntex Inc | Interleukin-1 formulation |
| DE4001451A1 (de) * | 1990-01-19 | 1991-08-01 | Octapharma Ag | Stabile injizierbare loesungen von faktor viii und faktor ix |
| JPH0565233A (ja) | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | モノクローナル抗体含有凍結乾燥製剤 |
| WO1992017207A1 (en) | 1991-03-26 | 1992-10-15 | Tanox Biosystems, Inc. | MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS |
| JP2966592B2 (ja) | 1991-07-20 | 1999-10-25 | 萩原 義秀 | 安定化されたヒトモノクローナル抗体製剤 |
| US6329509B1 (en) * | 1991-08-14 | 2001-12-11 | Genentech, Inc. | Anti-IgE antibodies |
| US6699472B2 (en) * | 1991-08-14 | 2004-03-02 | Genentech, Inc. | Method of treating allergic disorders |
| DK0602126T3 (da) | 1991-08-14 | 2003-06-16 | Genentech Inc | Immunoglobulinvarianter til specifikke FC epsilon-receptorer |
| GB9120304D0 (en) | 1991-09-24 | 1991-11-06 | Erba Carlo Spa | Stable pharmaceutical compositions containing a granulocyte macrophage colony stimulating factor |
| US5849700A (en) * | 1991-12-20 | 1998-12-15 | Novo Nordisk A/S | Pharmaceutical formulation |
| CH684164A5 (de) | 1992-01-10 | 1994-07-29 | Rotkreuzstiftung Zentrallab | Intravenös anwendbare Immunglobulinlösung. |
| DE69333928T2 (de) * | 1992-04-30 | 2006-08-17 | Probitas Pharma Inc., Los Angeles | Verbesserte solubilisierung und stabilisierung des faktor viii-komplexes |
| DE4344824C1 (de) | 1993-12-28 | 1995-08-31 | Immuno Ag | Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung |
| ATE401394T1 (de) | 1994-03-04 | 2008-08-15 | Genentech Inc | Verbesserte dnase flüssige lösungen |
| US5580856A (en) * | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
| GB9418092D0 (en) * | 1994-09-08 | 1994-10-26 | Red Cross Found Cent Lab Blood | Organic compounds |
| US5783738A (en) | 1994-12-28 | 1998-07-21 | Rhone-Poulenc Chimie | Optically active diphosphines, preparation thereof according to a process for the resolution of the racemic mixture and use thereof |
| US6037453A (en) * | 1995-03-15 | 2000-03-14 | Genentech, Inc. | Immunoglobulin variants |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| CA2226575C (en) | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| US6686191B1 (en) | 1995-09-22 | 2004-02-03 | Bayer Healthcare Llc | Preparation of virally inactivated intravenously injectable immune serum globulin |
| US5770700A (en) | 1996-01-25 | 1998-06-23 | Genetics Institute, Inc. | Liquid factor IX formulations |
| PL328199A1 (en) * | 1996-01-25 | 1999-01-18 | Schering Ag | Improved concentrated intravascular injection and infusion solutions |
| KR100236393B1 (ko) | 1996-02-02 | 1999-12-15 | 나까니시 히로유끼 | 사람성장호르몬을 함유하는 의약제제 |
| CA2244664C (en) | 1996-02-09 | 2008-06-03 | Amgen Inc. | Composition comprising interleukin-1 inhibitor and controlled release polymer |
| TW518219B (en) | 1996-04-26 | 2003-01-21 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
| GB9610992D0 (en) * | 1996-05-24 | 1996-07-31 | Glaxo Group Ltd | Concentrated antibody preparation |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| US6172213B1 (en) * | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
| US5994511A (en) * | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
| US6096872A (en) * | 1997-10-14 | 2000-08-01 | Ortho Diagnostic Systems, Inc. | Viral clearance process |
| US6541606B2 (en) * | 1997-12-31 | 2003-04-01 | Altus Biologics Inc. | Stabilized protein crystals formulations containing them and methods of making them |
| WO2000015260A1 (en) | 1998-09-16 | 2000-03-23 | Tanox, Inc. | Anti-ige gene therapy |
| GB9820525D0 (en) * | 1998-09-21 | 1998-11-11 | Allergy Therapeutics Ltd | Formulation |
| JP2000247903A (ja) | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
| CN1245216C (zh) | 1999-10-04 | 2006-03-15 | 希龙公司 | 稳定化的含多肽的液体药物组合物 |
| US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
| GB0023383D0 (en) * | 2000-09-23 | 2000-11-08 | Synprotec Ltd | 3,5-Bis (Trifluormethyl)Benzene derivatives |
| JPWO2002030464A1 (ja) | 2000-10-11 | 2004-02-19 | 江頭 健輔 | 新規肝疾患用薬 |
| JP4340062B2 (ja) | 2000-10-12 | 2009-10-07 | ジェネンテック・インコーポレーテッド | 粘度の減少した濃縮タンパク質製剤 |
| KR20100031769A (ko) | 2000-12-28 | 2010-03-24 | 알투스 파마슈티컬스 인코포레이티드 | 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법 |
| GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
| AU2002324556A1 (en) * | 2001-07-25 | 2003-02-17 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
| JP2005523882A (ja) * | 2001-10-16 | 2005-08-11 | アールエックスキネティックス，インコーポレイテッド | 高濃度タンパク質製剤および製造の方法 |
| ES2392073T3 (es) * | 2001-11-08 | 2012-12-04 | Abbott Biotherapeutics Corp. | Formulación farmacéutica líquida estable de anticuerpos IGG |
| CA2500895A1 (en) * | 2002-10-04 | 2004-04-15 | Forskarpatent I Syd Ab | Peptide-based passive immunization therapy for treatment of atherosclerosis |
| US20040191243A1 (en) * | 2002-12-13 | 2004-09-30 | Bei Chen | System and method for stabilizing antibodies with histidine |
| US20050158303A1 (en) * | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
| AU2004229335C1 (en) | 2003-04-04 | 2010-06-17 | Genentech, Inc. | High concentration antibody and protein formulations |
| US20060051347A1 (en) * | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| JP2009525986A (ja) * | 2006-02-03 | 2009-07-16 | メディミューン，エルエルシー | タンパク質製剤 |
| WO2008086395A2 (en) * | 2007-01-09 | 2008-07-17 | Wyeth | Anti-il-13 antibody formulations and uses thereof |
| AU2008342942A1 (en) * | 2007-12-28 | 2009-07-09 | Biolnvent International Ab | Formulation |
| EP2470210A2 (en) * | 2009-08-28 | 2012-07-04 | BioInvent International AB | Methods of treatment using anti-oxidized ldl antibodies |
-
2010
- 2010-03-05 BR BRPI1006519A patent/BRPI1006519A2/pt not_active IP Right Cessation
- 2010-03-05 MX MX2011009306A patent/MX2011009306A/es not_active Application Discontinuation
- 2010-03-05 CA CA2754528A patent/CA2754528A1/en not_active Abandoned
- 2010-03-05 TW TW099106511A patent/TW201039854A/zh unknown
- 2010-03-05 US US12/718,783 patent/US8318161B2/en not_active Expired - Fee Related
- 2010-03-05 WO PCT/US2010/026410 patent/WO2010102241A1/en not_active Ceased
- 2010-03-05 KR KR1020117023363A patent/KR20110128333A/ko not_active Ceased
- 2010-03-05 RU RU2011140498/10A patent/RU2011140498A/ru not_active Application Discontinuation
- 2010-03-05 AR ARP100100676A patent/AR076640A1/es unknown
- 2010-03-05 JP JP2011553145A patent/JP2012519706A/ja not_active Withdrawn
- 2010-03-05 AU AU2010221156A patent/AU2010221156A1/en not_active Abandoned
- 2010-03-05 SG SG2011063922A patent/SG174258A1/en unknown
- 2010-03-05 EP EP10707789A patent/EP2403874A1/en not_active Withdrawn
- 2010-03-05 CN CN2010800194416A patent/CN102414221A/zh active Pending
- 2010-03-05 PE PE2011001591A patent/PE20120359A1/es not_active Application Discontinuation
-
2011
- 2011-09-04 IL IL214956A patent/IL214956A0/en unknown
- 2011-09-06 ZA ZA2011/06503A patent/ZA201106503B/en unknown
- 2011-09-06 CL CL2011002194A patent/CL2011002194A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201039854A (en) | 2010-11-16 |
| CN102414221A (zh) | 2012-04-11 |
| US20100239567A1 (en) | 2010-09-23 |
| MX2011009306A (es) | 2011-10-13 |
| SG174258A1 (en) | 2011-10-28 |
| PE20120359A1 (es) | 2012-04-13 |
| IL214956A0 (en) | 2011-11-30 |
| CA2754528A1 (en) | 2010-09-10 |
| KR20110128333A (ko) | 2011-11-29 |
| AU2010221156A1 (en) | 2011-09-22 |
| CL2011002194A1 (es) | 2012-07-20 |
| ZA201106503B (en) | 2012-11-28 |
| US8318161B2 (en) | 2012-11-27 |
| WO2010102241A1 (en) | 2010-09-10 |
| JP2012519706A (ja) | 2012-08-30 |
| RU2011140498A (ru) | 2013-04-20 |
| AR076640A1 (es) | 2011-06-29 |
| EP2403874A1 (en) | 2012-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FIC20250029I1 (fi) | neratinibi | |
| PT3072906T (pt) | Formulação de anticorpos | |
| EP2358392A4 (en) | ANTIBODY FORMULATION | |
| FIC20230025I1 (fi) | neratinibi | |
| DK2459167T3 (da) | SUBKUTAN ANTI-HER2-antistofformulering | |
| PT2406284T (pt) | Anticorpos anti-bcma | |
| BRPI0820819A2 (pt) | Formulação de anticorpos | |
| BR112012030311A2 (pt) | anticorpo | |
| SI3342786T1 (sl) | Anti-DLL3 protitelo | |
| BRPI0907237A2 (pt) | Anticorpo anti-cldn6 | |
| HRP20171011T1 (hr) | ANTI-eMET ANTITIJELO | |
| ZA201204266B (en) | Antibody formulation | |
| IL214956A0 (en) | Antibody formulation | |
| ZA201203242B (en) | Antibody formulation | |
| DK2462134T3 (da) | N1-sulfonyl-5-fluorpyrimidinonderivater | |
| SI3703369T1 (sl) | Združevanje območij vzorcev | |
| ES2897500T8 (es) | Formulaciones de anticuerpos T1h | |
| EP2482848A4 (en) | Endoglin antibodies | |
| DK3620175T3 (da) | Højkoncentrerede antistofformuleringer | |
| BRPI1009465A2 (pt) | Formulação | |
| EP2629796A4 (en) | ANTIBODY | |
| EP2426149A4 (en) | ANTI-CADHERIN ANTIBODY | |
| EP2479211A4 (en) | FLUOR RUBBER COMPOSITION | |
| BRPI0920833A2 (pt) | preparação de benzonorborbenos | |
| BR112012003616A2 (pt) | metilpirroloprimidinacarboxamidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |